GlassScriptPhysician profile
Evany Rodriguez
NPI 1811399793
$3,036.72
in general payments reported to CMS, 2019-2025
29 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $777 · 2023: $879 · 2024: $208 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.82 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $583.32 | 2022-2025 | Jelmyto |
| Pfizer INC. | $284.51 | 2021-2025 | |
| Tolmar Pharmaceuticals, INC. | $262.25 | 2021-2022 | |
| Astellas Pharma US INC | $240.49 | 2021-2023 | Xtandi |
| Myriad Genetic Laboratories, INC. | $218.56 | 2021-2025 | Prolaris, Myrisk |
| 180 Medical, INC. | $213.71 | 2021-2025 | Gentlecath |
| Janssen Biotech, INC. | $151.23 | 2025 | Erleada |
| Abbvie INC. | $131.55 | 2021-2025 | |
| Blue Earth Diagnostics | $124.82 | 2021-2024 | |
| Coloplast Corp | $109.60 | 2023-2025 | Speedicath |
| Novartis Pharmaceuticals Corporation | $100.75 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $87.83 | 2023 | |
| Urovant Sciences INC | $83.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $68.92 | 2023-2025 | Gemtesa |
| C. R. Bard, INC. & Subsidiaries | $54.40 | 2024-2025 | Bard Urinary Drainage Bag |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $44.92 | 2021 | |
| Merck Sharp & Dohme LLC | $42.53 | 2022-2023 | Keytruda, Lynparza |
| Alnylam Pharmaceuticals INC. | $27.00 | 2023 | Oxlumo |
| Progenics Pharmaceuticals, INC. | $25.09 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.65 | 2021 | |
| Hologic Sales and Service, LLC | $21.42 | 2022 | |
| Tolmar, INC. | $20.07 | 2023 | |
| Ferring Pharmaceuticals INC. | $18.79 | 2025 | Adstiladrin |
| Ambu INC. | $17.10 | 2022 | |
| Boston Scientific Corporation | $17.06 | 2024 | Spaceoar Vue System - 10ml |
| Endo Pharmaceuticals INC. | $16.85 | 2021 | |
| Foundation Medicine, INC. | $16.32 | 2022 | |
| Clarus Therapeutics INC. | $15.49 | 2021 | |
| Philips North America LLC | $14.38 | 2025 | Oncology Solution |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evany Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.